COMBINAISON D'HYDROMORPHONE ET DE NALOXONE A UTILISER DANS LE TRAITEMENT DE LA DOULEUR CHEZ DES PATIENTS SOUFFRANT DE DOULEUR ET D'UNE MALADIE ENTRAINANT UNE DYSBIOSE INTESTINALE ET/OU L'AUGMENTATION DU RISQUE DE TRANSLOCATION BACTERIENNE INTESTINALE
The present invention is concerned with an oral pharmaceutical dosage form comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, SIRS and/or sepsis.
